sur Moderna, Inc. (NASDAQ:MRNA)
Moderna to Present mRNA Therapeutics Data at ESMO Congress 2025
Moderna, Inc. (NASDAQ: MRNA) has announced that three abstracts on its investigational mRNA therapeutics will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The event will take place from October 17 to 21. Key presentations will highlight Moderna's mRNA-4359, a therapy designed to trigger T-cell immune responses against tumors, and intismeran autogene (V940/mRNA-4157), co-developed with Merck.
A mini oral presentation, scheduled for October 17, will delve into clinical outcomes of mRNA-4359 when combined with pembrolizumab in treating resistant melanoma. Additionally, two poster presentations will explore intismeran autogene's efficacy in bladder cancer and as a first-line therapy for advanced melanoma.
Moderna will also host an analyst event during the ESMO Congress to provide further insights into their developments.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Moderna, Inc.